LONG-TERM FOLLOW-UP OF COMBINATION CHEMOTHERAPY-RADIOTHERAPY OF STAGE III HODGKINS-DISEASE - CANCER AND ACUTE-LEUKEMIA GROUP-B STUDY

The Cancer and Acute Leukemia Group B studied the effect of combination chemotherapy‐radiotherapy on Stage III Hodgkin's disease. Chemotherapy consisting of 4 weekly doses of vinblastine and one dose of mechlorethamine hydrochloride was followed by no therapy (CT), radiation to involved fields (CTIF) or total nodal radiation (CTTN). Two other treatment arms included total nodal radiation alone (TN) or total nodal radiation followed by chemotherapy (TNCT). Maximum follow‐up is ten years. Complete remission percentages were 36 (8/22) for CT, 71 (17/24) for CTIF, 100 (21/21) for CTTN, 86 (19/22) for TNCT and 89 (16/18) for TN. Disease‐free survival in patients receiving radiation ± chemotherapy is 23%(19/73) at 5 years, but even after 9 years relapses were observed in two patients. Forty‐one percent of all patients are alive and 32% have survived for five years. Ability to administer adequate therapy was the main determinant for response duration and survival. Factors influencing the outcome of the disease include histology, age, splenectomy, initial white blood cell count and performance status, whereas symptomatology, initial absolute lymphocyte count and sex played no role on survival. Copyright © 1979 American Cancer Society